Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07000149 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
A Phase 3 study of Advanced Clear Cell Renal Cell Carcinoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,116
- Enrollment target
- 20
- Study locations
NCT07000149: Active Phase 3 study of Advanced Clear Cell Renal Cell Carcinoma, sponsored by AstraZeneca.
NCT07000149 is a Phase 3 study of Advanced Clear Cell Renal Cell Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,116 participants, above the 140-participant average among 7 other Advanced Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (697% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07000149, a Phase 3 study of Advanced Clear Cell Renal Cell Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,116 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell carcinoma (ccRCC).
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Volrustomig
- DRUG Casdatifan
Study Locations (20)
Other
- Research Site - East Melbourne
- Research Site - Elizabeth Vale
- Research Site - North Adelaide
- Research Site - Syndey
- Research Site - Beijing
- Research Site - Guangzhou
- Research Site - Nanjing
- Research Site - Nanning
- Research Site - Shanghai
- Research Site - Xiamen
- Research Site - Batumi
- Research Site - Tbilisi
- Research Site - Tbilisi
California
- Research Site - La Jolla
Colorado
- Research Site - Aurora
Massachusetts
- Research Site - Boston
New York
- Research Site - New York
Ohio
- Research Site - Cleveland
Tennessee
- Research Site - Nashville
Texas
- Research Site - Lubbock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,116 participants |
| Start Date | 2025-07-28 |
| Est. Completion | 2032-07-29 |
| Phase | Phase 3 |
What the registry record for NCT07000149 still lists
NCT07000149 is an interventional study that assigns participants to a tested intervention. Its 1,116 participants enrollment target places it among the larger protocols in the corpus, above the 140-participant average among 7 other Advanced Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (697% higher).
The record links to 1 condition, with Advanced Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT07000149 names 20 study sites across 8 states, led by Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT07000149 about?
NCT07000149 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC". This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell carcinoma (ccRCC).
What is the current status of trial NCT07000149?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,116 participants. The study started on 2025-07-28. Estimated completion is 2032-07-29.
What conditions does trial NCT07000149 study?
This clinical trial studies the following conditions: Advanced Clear Cell Renal Cell Carcinoma.
What interventions are being tested in trial NCT07000149?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Volrustomig (DRUG), Casdatifan (DRUG).
Who is sponsoring clinical trial NCT07000149?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07000149 being conducted?
This trial has 20 study locations across California, Colorado, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 3
-
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
RECRUITING · Phase 1
-
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
RECRUITING · Phase 2
-
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
ACTIVE NOT RECRUITING · Phase 1
-
177LuPSMA in Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI